Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The RNA code comes into focus.

Nature·2017
Same author

Epidemiology: Rising in the East.

Nature·2016
Same author

The dark side of the human genome.

Nature·2016
Same author

Biomedicine: A rare opportunity.

Nature·2016
Same author

Outlook for NGF inhibitor painkiller class brightens.

Nature biotechnology·2016
Same author

Drug developers delve into the cell's trash-disposal machinery.

Nature reviews. Drug discovery·2016

Related Experiment Video

Updated: May 9, 2026

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

Revolution dawning in cardiotoxicity testing

Kelly Rae Chi

    Nature Reviews. Drug Discovery
    |August 2, 2013
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
    08:09

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

    Published on: June 7, 2018

    Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
    08:07

    Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

    Published on: April 7, 2023

    Related Experiment Videos

    Last Updated: May 9, 2026

    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
    14:03

    High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

    Published on: March 24, 2023

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
    08:09

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

    Published on: June 7, 2018

    Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
    08:07

    Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

    Published on: April 7, 2023